Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 66

Sort by

Sort Order Select

Journal Articles

Suboptimal/Reduced Therapy in Older Patients with T-Cell Lymphoma Resulted in Poorer Outcomes: Report from the International T-Cell Project 1.0

Tetiana Skrypets, Onder Alpdogan, Luana Conte, Monica Civallero, Athina Lymboussaki, Julie M. Vose, Ivan Dlouhy, Maria Elena Cabrera, Felicitas Hitz, Sabela Bobillo, Won Seog Kim, Arnon Nagler, Dario Marino, Ranjana H. Advani, Caterina Stelitano, Pierluigi Porcu, Massimo Federico

Blood (2024) 144 (Supplement 1): 6402.

https://doi.org/10.1182/blood-2024-203976

Published: 2024

Journal Articles

Clinical Impact of Serum Ferritin Levels and EBV-Positivity in Nodal T-Cell Lymphomas

Suraj Nyalakonda, Madeline Williams, Roxanna Fouladi, Adrian Altieri, Michael Dimino, Quinto John Gesiotto, Rebecca Masel, Safiyyah Bhatti, Onder Alpdogan, Jerald Gong, Alan S Khoo, Pierluigi Porcu

Blood (2024) 144 (Supplement 1): 6415.

https://doi.org/10.1182/blood-2024-209306

Published: 2024

Journal Articles

Open Label Single Arm Study to Assess the Implementation of Home Based Daratumumab Administration in Patients Being Treated for Multiple Myeloma

Adam F. Binder, Ubaldo Martinez Outschoorn, Carol Gung, Alexandra Cohen, Mallika Saini, Onder Alpdogan, Pierluigi Porcu, Kristin L Rising

Blood (2024) 144 (Supplement 1): 7596.

https://doi.org/10.1182/blood-2024-206031

Published: 2024

Journal Articles

A Phase Ib/II Study Evaluating Navitoclax after Failure of Hypomethylating Agent and Venetoclax for Treatment of Relapsed or Refractory High-Risk Myelodysplastic Syndrome

Gina Keiffer, Sara E. Meyer, Christine Eischen, Ubaldo Martinez Outschoorn, Onder Alpdogan, Adam F. Binder, Pierluigi Porcu, Lindsay Wilde, Margaret Kasner, Neil Palmisiano

Blood (2023) 142 (Supplement 1): 1551.

https://doi.org/10.1182/blood-2023-186765

Published: 2023

Journal Articles

Phase II, Single Arm, Open Label, Single Center Study of Obinutuzumab and Ibrutinib in the Front Line Treatment of Indolent B-Cell Non-Hodgkin Lymphomas

Blood (2023) 142 (Supplement 1): 3028.

https://doi.org/10.1182/blood-2023-187847

Published: 2023

Journal Articles

PET4 Response As an Independent Predictor of Long-Term Outcomes in ECHELON2 (A+CHP Vs. CHOP) in CD30+PTCL

Blood (2023) 142 (Supplement 1): 3074.

https://doi.org/10.1182/blood-2023-184933

Published: 2023

Journal Articles

A Two-Part Study Evaluating the Combination of Tazemetostat and CPX-351 (Part 1) and Palbociclib with CPX-351 (Part 2) for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia

Gina Keiffer, Bruno Calabretta, Alexander Mazo, Ubaldo Martinez Outschoorn, Onder Alpdogan, Adam F. Binder, Pierluigi Porcu, Lindsay Wilde, Margaret Kasner

Blood (2023) 142 (Supplement 1): 1550.

https://doi.org/10.1182/blood-2023-186671

Published: 2023

Journal Articles

Nanatinostat (Nstat) and Valganciclovir (VGCV) in Relapsed/Refractory (R/R) Epstein-Barr Virus-Positive (EBV + ) Lymphomas: Final Results from the Phase 1b/2 VT3996-201 Study

Bradley M. Haverkos, Onder Alpdogan, Robert Baiocchi, Jonathan E Brammer, Tatyana A. Feldman, Marcelo Capra, Elizabeth A Brem, Santosh M Nair, Phillip Scheinberg, Juliana Pereira, Leyla Shune, Erel Joffe, Afton Katkov, Robert McRae, Ivor Royston, Lisa Rojkjaer, Pierluigi Porcu

Blood (2021) 138 (Supplement 1): 623.

https://doi.org/10.1182/blood-2021-152603

Published: 2021

Journal Articles

COVID-19 in Patients with Hematologic Malignancies: A Single-Center Experience

Lindsay Wilde, MD, Adam F. Binder, MD, Matthew Carabasi, MD, Joanne Filicko-O'Hara, MD, John L. Wagner, MD, Onder Alpdogan, MD, Margaret Kasner, MDMSc, Thomas R. Klumpp, MD, Ubaldo Martinez-Outschoorn, MD, Neil Palmisiano, MDMS, Gina Keiffer, MD, Dolores Grosso, DNP, CRNP, Michael Millenson, Amy R. MacKenzie, MD, Allison Zibelli, MD, Neal Flomenberg, MD, Pierluigi Porcu, MD, Usama Gergis, MD

Blood (2020) 136 (Supplement 1): 36–37.

https://doi.org/10.1182/blood-2020-140719

Published: 2020

Journal Articles

Vaccination Response after Autologous Stem Cell Transplantation

Onder Alpdogan, MD, Jennifer Hong, MD, Thomas R. Klumpp, MD, Abdullateef O Abdulkareem, MD MPH, Adam F. Binder, MD, Matthew Carabasi, MD, Joanne Filicko-O'Hara, MD, Dolores Grosso, DNP, CRNP, Margaret Kasner, MDMSc, Ubaldo Martinez-Outschoorn, MD, Neil Palmisiano, MDMS, Lindsay Wilde, MD, Pierluigi Porcu, MD, Usama Gergis, MD, John L. Wagner, MD, Neal Flomenberg, MD

Blood (2020) 136 (Supplement 1): 25–26.

https://doi.org/10.1182/blood-2020-141269

Published: 2020

Journal Articles

Oral Nanatinostat (Nstat) and Valganciclovir (VGCV) in Patients with Recurrent Epstein-Barr Virus (EBV)-Positive Lymphomas: Initial Phase 2 Results

Pierluigi Porcu, MD, Bradley Haverkos, MD MPH, MS, Onder Alpdogan, MD, Robert Baiocchi, MD PhD, Jonathan E Brammer, MD, Tatyana A. Feldman, MD, Marcelo Capra, MD PhD, Elizabeth A Brem, MD, Phillip Scheinberg, MD, Juliana Pereira, MD PhD, Leyla Shune, MD, Afton Katkov, MSc, Robert McRae, Lisa Rojkjaer, MD, Ivor Royston, MD, Douglas V. Faller, MD PhD

Blood (2020) 136 (Supplement 1): 7–8.

https://doi.org/10.1182/blood-2020-140843

Published: 2020

Journal Articles

Successful Treatment of Mature T-Cell Lymphoma with Allogeneic Stem Cell Transplantation: The Largest Multicenter Retrospective Analysis

Blood (2020) 136 (Supplement 1): 35–36.

https://doi.org/10.1182/blood-2020-138542

Published: 2020

Journal Articles

Combination of Oral Nanatinostat (Nstat), a Novel Histone Deacetylase Inhibitor (HDACi), and the Oral Anti-Viral, Valganciclovir (VGCV), Is Active in Relapsed/Refractory (R/R) Epstein-Barr Virus (EBV)-Positive B-Cell, T-Cell, and Hodgkin Lymphoma: Interim Safety and Efficacy Results from a Phase 1b/2a Study

Blood (2019) 134 (Supplement_1): 465.

https://doi.org/10.1182/blood-2019-132004

Published: 2019

Journal Articles

An Exploratory Analysis of Brentuximab Vedotin Plus CHP (A+CHP) in the Frontline Treatment of Patients with CD30+ Peripheral T-Cell Lymphomas (ECHELON-2): Impact of Consolidative Stem Cell Transplant

Blood (2019) 134 (Supplement_1): 464.

https://doi.org/10.1182/blood-2019-122781

Published: 2019

Journal Articles

Results of a Phase I/II Study of Bendamustine in Combination with Ofatumumab, Carboplatin and Etoposide (BOCE) for Relapsed or Refractory Aggressive B-Cell Non-Hodgkin Lymphomas

Jonathan Pan, MD, Sushil Ghimire, MD, Tingting Zhan, PhD, Onder Alpdogan, MD, Andrew E. Chapman, DO, Matthew Carabasi, MD, Ubaldo Martinez-Outschoorn, MD, Lewis J. Rose, MD, Michael Ramirez, MD, John L Wagner, MD, Barbara Pro, MD, Mark A. Weiss, MD, Neal Flomenberg, MD, Pierluigi Porcu, MD, Joanne Filicko-O'Hara, MD, Sameh Gaballa, MD

Blood (2019) 134 (Supplement_1): 5318.

https://doi.org/10.1182/blood-2019-125836

Published: 2019

Journal Articles

2 Step Myeloablative Haploidentical Transplant (HI MA HSCT) in Intermediate and High-Risk Patients-Changing the Timing of the 2 Step Approach

Dolores Grosso, DNP, CRNP, Onder Alpdogan, MD, Matthew Carabasi, MD, Joanne Filicko-O'Hara, MD, Sameh Gaballa, MD, Margaret Kasner, MD, Thomas R. Klumpp, MD, Ubaldo Martinez-Outschoorn, MD, Neil Palmisiano, MD, William O'Hara, PharmD, John L Wagner, MD, Pierluigi Porcu, MD, Neal Flomenberg, MD

Blood (2018) 132 (Supplement 1): 4661.

https://doi.org/10.1182/blood-2018-99-110815

Published: 2018

Journal Articles

HSCT Engraftment Kinetics: Differences in Chimerism between Haploidentical (HI) and Matched Related (MR) Transplant Recipients (HSCT) after the 2 Step Approach

Dolores Grosso, DNP, CRNP, Onder Alpdogan, MD, Matthew Carabasi, MD, Joanne Filicko-O'Hara, MD, Sameh Gaballa, MD, Margaret Kasner, MD, Thomas R. Klumpp, MD, Ubaldo Martinez-Outschoorn, MD, Neil Palmisiano, MD, Pierluigi Porcu, MD, William O'Hara, PharmD, John L Wagner, MD, Neal Flomenberg, MD

Blood (2018) 132 (Supplement 1): 3371.

https://doi.org/10.1182/blood-2018-99-117364

Published: 2018

Journal Articles

Differences in Allogeneic Product T-Cell Subsets According to Donor Age: Associations with Immune Reconstitution and Acute Graft Versus Host Disease (aGVHD) in Haploidentical (HI) Hematopoietic Stem Cell Transplantation (HSCT)

Jason Chen, MD, Jonathan Pan, MD, John L. Wagner, MD, Michael Sun, Onder Alpdogan, MD, Matthew Carabasi, MD, Joanne Filicko-O'Hara, MD, Sameh Gaballa, MD, Margaret Kasner, MD, Thomas Klumpp, MD, Neil Palmisiano, MD, Ubaldo Martinez-Outschoorn, MD, Pierluigi Porcu, MD, Neal Flomenberg, MD, Dolores Grosso, DNP, CRNP

Blood (2017) 130 (Supplement 1): 3200.

https://doi.org/10.1182/blood.V130.Suppl_1.3200.3200

Published: 2017

Journal Articles

The Presence of Recipient CMV Immunodominant Human Leukocyte Antigen (HLA) Alleles Affect Outcomes after Haploidentical (HI) Hematopoietic Stem Cell Transplantation (HSCT)

Dolores Grosso, DNP, CRNP, Onder Alpdogan, MD, Matthew Carabasi, MD, Joanne Filicko-O'Hara, MD, Sameh Gaballa, MD, Margaret Kasner, MD, Thomas Klumpp, MD, Ubaldo Martinez-Outschoorn, MD, William O'Hara, PharmD, Neil Palmisiano, MD, John L. Wagner, MD, Pierluigi Porcu, MD, Neal Flomenberg, MD

Blood (2017) 130 (Supplement 1): 1959.

https://doi.org/10.1182/blood.V130.Suppl_1.1959.1959

Published: 2017

Journal Articles

A Phase II Trial of Sirolimus with Standard Induction Chemotherapy in Patients with De Novo Acute Myeloid Leukemia

Neil Palmisiano, MD, Grace Jeschke, PhD, Benjamin E Leiby, PhD, Onder Alpdogan, MD, Matthew Carabasi, MD, Joanne Filicko-O'Hara, MD, Sameh Gaballa, MD, Dolores Grosso, DNP, CRNP, Thomas R. Klumpp, MD, Ubaldo Martinez Outschoorn, MD, John L Wagner, MD, Martin Carroll, MD, Pierluigi Porcu, MD, Neal Flomenberg, MD, Alexander E. Perl, MD, Margaret Kasner, MD

Blood (2017) 130 (Supplement 1): 3858.

https://doi.org/10.1182/blood.V130.Suppl_1.3858.3858

Published: 2017

NARROW

Suboptimal/Reduced Therapy in Older Patients with T-Cell Lymphoma Resulted in Poorer Outcomes: Report from the International T-Cell Project 1.0

Clinical Impact of Serum Ferritin Levels and EBV-Positivity in Nodal T-Cell Lymphomas

Open Label Single Arm Study to Assess the Implementation of Home Based Daratumumab Administration in Patients Being Treated for Multiple Myeloma

A Phase Ib/II Study Evaluating Navitoclax after Failure of Hypomethylating Agent and Venetoclax for Treatment of Relapsed or Refractory High-Risk Myelodysplastic Syndrome

Phase II, Single Arm, Open Label, Single Center Study of Obinutuzumab and Ibrutinib in the Front Line Treatment of Indolent B-Cell Non-Hodgkin Lymphomas

PET4 Response As an Independent Predictor of Long-Term Outcomes in ECHELON2 (A+CHP Vs. CHOP) in CD30+PTCL

A Two-Part Study Evaluating the Combination of Tazemetostat and CPX-351 (Part 1) and Palbociclib with CPX-351 (Part 2) for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia

Nanatinostat (Nstat) and Valganciclovir (VGCV) in Relapsed/Refractory (R/R) Epstein-Barr Virus-Positive (EBV + ) Lymphomas: Final Results from the Phase 1b/2 VT3996-201 Study

COVID-19 in Patients with Hematologic Malignancies: A Single-Center Experience

Vaccination Response after Autologous Stem Cell Transplantation

Oral Nanatinostat (Nstat) and Valganciclovir (VGCV) in Patients with Recurrent Epstein-Barr Virus (EBV)-Positive Lymphomas: Initial Phase 2 Results

Successful Treatment of Mature T-Cell Lymphoma with Allogeneic Stem Cell Transplantation: The Largest Multicenter Retrospective Analysis

An Exploratory Analysis of Brentuximab Vedotin Plus CHP (A+CHP) in the Frontline Treatment of Patients with CD30+ Peripheral T-Cell Lymphomas (ECHELON-2): Impact of Consolidative Stem Cell Transplant

Results of a Phase I/II Study of Bendamustine in Combination with Ofatumumab, Carboplatin and Etoposide (BOCE) for Relapsed or Refractory Aggressive B-Cell Non-Hodgkin Lymphomas

2 Step Myeloablative Haploidentical Transplant (HI MA HSCT) in Intermediate and High-Risk Patients-Changing the Timing of the 2 Step Approach

HSCT Engraftment Kinetics: Differences in Chimerism between Haploidentical (HI) and Matched Related (MR) Transplant Recipients (HSCT) after the 2 Step Approach

Differences in Allogeneic Product T-Cell Subsets According to Donor Age: Associations with Immune Reconstitution and Acute Graft Versus Host Disease (aGVHD) in Haploidentical (HI) Hematopoietic Stem Cell Transplantation (HSCT)

The Presence of Recipient CMV Immunodominant Human Leukocyte Antigen (HLA) Alleles Affect Outcomes after Haploidentical (HI) Hematopoietic Stem Cell Transplantation (HSCT)

A Phase II Trial of Sirolimus with Standard Induction Chemotherapy in Patients with De Novo Acute Myeloid Leukemia

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only